Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?

Teixeira, Fabio Vieira; Parra, Rogerio Serafim; Feres, Omar; Kotze, Paulo Gustavo

Teixeira, Fabio Vieira; Parra, Rogerio Serafim; Feres, Omar; Kotze, Paulo Gustavo.

Teixeira, Fabio Vieira; Clinica Gastrosaude. Marilia. BR
Parra, Rogerio Serafim; Universidade de Sao Paulo. Faculdade de Medicina de Ribeirao Preto. Ribeirão Preto. BR
Feres, Omar; Universidade de Sao Paulo. Faculdade de Medicina de Ribeirao Preto. Ribeirão Preto. BR
Kotze, Paulo Gustavo; Universidade Catolica do Parana (PUCPR). Curitiba. BR

Clinics ; 74: e1424, 2019.

Article in English | LILACS | ID: biblio-1039579

Subject(s)

Humans; Crohn Disease; Gastrointestinal Agents; Brazil; Infliximab; Antibodies, Monoclonal

Fulltext

XML

Search on Google

Full text: Available Index: LILACS (Americas) Main subject: Crohn Disease Limits: Humans Country/Region as subject: South America / Brazil Language: English Journal: Clinics Journal subject: Medicine Year: 2019 Type: Article Affiliation country: Brazil Institution/Affiliation country: Clinica Gastrosaude/BR / Universidade Catolica do Parana (PUCPR)/BR / Universidade de Sao Paulo/BR

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google